[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575043":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":42,"responsibleParty":234,"collaborators":26,"id":236,"slug":26,"hasResults":237,"nctId":238,"briefTitle":239,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":237,"sex":242,"minAge":243,"maxAge":26,"enrollmentInfo":244,"targetDuration":26,"studyType":247,"phases":248,"briefSummary":250,"conditions":251,"keywords":253,"overallStatus":45,"whyStopped":26,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":269},{"fullName":5,"class":6},"University Hospital, Toulouse","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intensive biomarkers-guided arm","EXPERIMENTAL","A second infusion when crosslaps levels reach 300 pg\u002FmL, no later than month-12",[13],"Drug: a second infusion of ZOL when crosslaps levels reach 300 pg\u002FmL",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard treatment arm","ACTIVE_COMPARATOR","Potentially a rescue second infusion at month-12, in case unfavourable outcome (incident osteoporotic fractures) or high risk of unfavourable outcome",[19],"Drug: a rescue second infusion at month-12 (standard traitment)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","a second infusion of ZOL when crosslaps levels reach 300 pg\u002FmL","a first infusion of ZOL 5 mg, 6 months after denosumab withdrawal (= study start) and a second infusion when crosslaps levels reach 300 pg\u002FmL, no later than month-12",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"a rescue second infusion at month-12 (standard traitment)","a first infusion of ZOL 5 mg, 6 months after denosumab withdrawal (= study start), and potentially a rescue second infusion at month-12, in case unfavourable outcome (incident osteoporotic fractures) or high risk of unfavourable outcome",[15],[32,38],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Yannick DEGBOE, MD","CONTACT","05 61 77 73 75","+33","degboe.y@chu-toulouse.fr",{"name":39,"role":34,"phone":40,"phoneExt":36,"email":41},"Charline DAGUZAN","05 61 77 84 90","daguzan.c@chu-toulouse.fr",[43,57,68,79,90,101,113,124,135,146,157,168,179,187,198,209,220],{"facility":44,"status":45,"city":46,"state":26,"zip":26,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Amiens Hospital","RECRUITING","Amiens","France",{"type":49,"coordinates":50},"Point",[51,52],2.3,49.9,{"lat":52,"lon":51},[55],{"name":56,"role":34,"phone":26,"phoneExt":26,"email":26},"Vincent GOEB",{"facility":58,"status":45,"city":59,"state":26,"zip":26,"country":47,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Bordeaux Hospital","Bordeaux",{"type":49,"coordinates":61},[62,63],-0.58046,44.84124,{"lat":63,"lon":62},[66],{"name":67,"role":34,"phone":26,"phoneExt":26,"email":26},"Nadia MEHSEN",{"facility":69,"status":45,"city":70,"state":26,"zip":26,"country":47,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Cahors Hospital","Cahors",{"type":49,"coordinates":72},[73,74],1.43663,44.4491,{"lat":74,"lon":73},[77],{"name":78,"role":34,"phone":26,"phoneExt":26,"email":26},"Slim LASSOUED",{"facility":80,"status":45,"city":81,"state":26,"zip":26,"country":47,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"Dax Hospital","Dax",{"type":49,"coordinates":83},[84,85],-1.05366,43.71032,{"lat":85,"lon":84},[88],{"name":89,"role":34,"phone":26,"phoneExt":26,"email":26},"Emilie SHIPLEY",{"facility":91,"status":45,"city":92,"state":26,"zip":26,"country":47,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Le Mans Hospital","Le Mans",{"type":49,"coordinates":94},[95,96],0.20251,48.0021,{"lat":96,"lon":95},[99],{"name":100,"role":34,"phone":26,"phoneExt":26,"email":26},"Guillaume DIREZ",{"facility":102,"status":103,"city":104,"state":26,"zip":26,"country":47,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"Lille Hospital","NOT_YET_RECRUITING","Lille",{"type":49,"coordinates":106},[107,108],3.05512,50.63391,{"lat":108,"lon":107},[111],{"name":112,"role":34,"phone":26,"phoneExt":26,"email":26},"Bernard CORTET",{"facility":114,"status":45,"city":115,"state":26,"zip":26,"country":47,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Limoges Hospital","Limoges",{"type":49,"coordinates":117},[118,119],1.24759,45.83362,{"lat":119,"lon":118},[122],{"name":123,"role":34,"phone":26,"phoneExt":26,"email":26},"Anna BILLO",{"facility":125,"status":45,"city":126,"state":26,"zip":26,"country":47,"cosmosGeoPoint":127,"geoPoint":131,"contacts":132},"Marseille Hsopital","Marseille",{"type":49,"coordinates":128},[129,130],5.38107,43.29695,{"lat":130,"lon":129},[133],{"name":134,"role":34,"phone":26,"phoneExt":26,"email":26},"Sophie TRIJAU",{"facility":136,"status":45,"city":137,"state":26,"zip":26,"country":47,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"Montpellier Hospital","Montpellier",{"type":49,"coordinates":139},[140,141],3.87635,43.61093,{"lat":141,"lon":140},[144],{"name":145,"role":34,"phone":26,"phoneExt":26,"email":26},"Paulina SZAFORS",{"facility":147,"status":45,"city":148,"state":26,"zip":26,"country":47,"cosmosGeoPoint":149,"geoPoint":153,"contacts":154},"Nice Hospital","Nice",{"type":49,"coordinates":150},[151,152],7.26608,43.70313,{"lat":152,"lon":151},[155],{"name":156,"role":34,"phone":26,"phoneExt":26,"email":26},"Veronique BREUIL",{"facility":158,"status":45,"city":159,"state":26,"zip":26,"country":47,"cosmosGeoPoint":160,"geoPoint":164,"contacts":165},"Orléans Hospital","Orléans",{"type":49,"coordinates":161},[162,163],1.90407,47.90248,{"lat":163,"lon":162},[166],{"name":167,"role":34,"phone":26,"phoneExt":26,"email":26},"Eric LESPESSAILLES",{"facility":169,"status":45,"city":170,"state":26,"zip":26,"country":47,"cosmosGeoPoint":171,"geoPoint":175,"contacts":176},"Cochin Hospital","Paris",{"type":49,"coordinates":172},[173,174],2.3488,48.85341,{"lat":174,"lon":173},[177],{"name":178,"role":34,"phone":26,"phoneExt":26,"email":26},"Karine BRIOT",{"facility":180,"status":45,"city":170,"state":26,"zip":26,"country":47,"cosmosGeoPoint":181,"geoPoint":183,"contacts":184},"Lariboisiere Hospital",{"type":49,"coordinates":182},[173,174],{"lat":174,"lon":173},[185],{"name":186,"role":34,"phone":26,"phoneExt":26,"email":26},"Thomas FUNCK-BRENTANO",{"facility":188,"status":45,"city":189,"state":26,"zip":26,"country":47,"cosmosGeoPoint":190,"geoPoint":194,"contacts":195},"Poitiers Hospital","Poitiers",{"type":49,"coordinates":191},[192,193],0.34348,46.58261,{"lat":193,"lon":192},[196],{"name":197,"role":34,"phone":26,"phoneExt":26,"email":26},"Guillaume LARID",{"facility":199,"status":45,"city":200,"state":26,"zip":26,"country":47,"cosmosGeoPoint":201,"geoPoint":205,"contacts":206},"Rennes Hospital","Rennes",{"type":49,"coordinates":202},[203,204],-1.67431,48.11109,{"lat":204,"lon":203},[207],{"name":208,"role":34,"phone":26,"phoneExt":26,"email":26},"François ROBIN",{"facility":210,"status":45,"city":211,"state":26,"zip":26,"country":47,"cosmosGeoPoint":212,"geoPoint":216,"contacts":217},"Saint Etienne Hospital","Saint-Etienne",{"type":49,"coordinates":213},[214,215],4.39,45.43389,{"lat":215,"lon":214},[218],{"name":219,"role":34,"phone":26,"phoneExt":26,"email":26},"Thierry THOMAS",{"facility":221,"status":45,"city":222,"state":26,"zip":26,"country":47,"cosmosGeoPoint":223,"geoPoint":227,"contacts":228},"Toulouse Hospital","Toulouse",{"type":49,"coordinates":224},[225,226],1.44367,43.60426,{"lat":226,"lon":225},[229,231],{"name":230,"role":34,"phone":26,"phoneExt":26,"email":26},"Yannick DEGBOE",{"name":232,"role":233,"phone":26,"phoneExt":26,"email":26},"Anna GOSSET","SUB_INVESTIGATOR",{"type":235,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100575043",false,"NCT06767150","StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis","SAFEST","Inclusion Criteria:\n\n* Women with post-menopausal osteoporosis\n* And treated with denosumab for at least 2 years and reaching decision of denosumab withdrawal because of achieved therapeutic target defined as no fracture during treatment; no new risk factors; no BMD decrease \\> 0.03 g\u002Fcm² at the spine or hip;\n* And with a history of severe fracture or a femoral or lumbar T-score ≤ -2.5 prior denosumab initiation.\n\nExclusion Criteria:\n\n* Dmab use for bone disease other than post-menopausal osteoporosis.\n* Uncontrolled endocrine diseases. Liver failure.\n* Use of medication affecting bone metabolism during the last year, including bisphosphonates, teriparatide, romosozumab, Selective Estrogen Receptor Modulators, breast cancer hormonotherapy, glucocorticoids over 5 mg\u002Fday.\n* Contra-indication to bisphosphonates according to license recommendation including chronic kidney disease with GFR stage \\> or = G3b. Prior intolerance to zoledronic acid.\n* Subjects unable to give an informed consent or to fill the case report form. Subjects under law protection.\n* Foreseeable poor compliance with the strategy, alcoholism, toxicomania.","FEMALE","18 Years",{"count":245,"type":246},200,"ESTIMATED","INTERVENTIONAL",[249],"PHASE4","Denosumab (Dmab) is a treatment for postmenopausal osteoporosis. However, its withdrawal is associated with a rebound phenomenon associated with an unexpected increased risk of vertebral fractures. Defining the optimal strategy for Dmab withdrawal is critically needed. Investigator propose an open-label randomized superiority strategy trial to compare the 1-year lumbar densitometric efficacy of biomarkers-driven zoledronate (ZOL) infusion vs standardized ZOL treatment to mitigate rebound phenomenon.",[252],"Postmenopausal Osteoporosis",[254,255,256,257,258,259],"Postmenopausal osteoporosis","strategy","denosumab","zoledronate","rebound","withdrawal","2025-12-23",{"date":262,"type":263},"2025-12-31","ACTUAL",{"date":265,"type":263},"2025-10-02",{"date":267,"type":246},"2030-10",{"name":5,"class":6},17]